A Comparing Study Between SJ04 and Ovidrel® in Healthy Subjects
A legfontosabb adatok
- Ki végzi
- Suzhou Centergene Pharmaceuticals Co.,Ltd.
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1. fázis
- Résztvevők
- 48 fő, tervezett
- Kezdés
- 2024. aug. 12.
- Várható befejezés
- 2026. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- T-R (Test-Reference drug)
- R-T (Reference-Test drug)
- A regiszteradat frissítve
- 2025. február 10.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for healthy women in China. It compares how the body handles two injected drugs, SJ04 and Ovidrel®.
- Életkor
- 20 to 40 years
- Nem
- Women only
- Korábbi kezelés
- Cannot join after using any LH preparation, hMG or hCG preparation within 3 months before screening. No prescription medicines within 14 days or 5 half-lives before screening. No over-the-counter medicines within 7 days or 5 half-lives before screening.
- Biomarker vagy leletérték
- Hormone levels (FSH, LH, PRL, E2, P, T) must be normal or not clinically significant. LH must be <5 IU/L and FSH <4 IU/L at Day -1. Weight at least 45.0 kg (99 lb) and body mass index 19.0~26.0 kg/m2. Regular menstrual cycle of 25-34 days.
A részvétel fő kizáró okai
- Pregnant, breastfeeding, a positive pregnancy test, or planning children during the trial and for 3 months after
- Past or current tumors or diseases of the hypothalamus, pituitary, ovaries, uterus or breast, polycystic ovary syndrome or OHSS
- Ectopic pregnancy within 3 months before screening
- Positive test for hepatitis B, hepatitis C, HIV or syphilis
- Drug abuse, more than 14 units of alcohol per week, or smoking at least 5 cigarettes per day
Ez a vizsgálat csak egészséges résztvevőket keres. A regiszter mondata, amelyen ez alapul: 1. Healthy female subjects aged 20 to 40 years old (including boundary values).
A regiszter feltételei, szó szerint
Mind a 24 feltétel megnézéseKevesebb
Ki vehet részt
- Healthy female subjects aged 20 to 40 years old (including boundary values)
- Weight not less than 45.0 kg, body mass index within the range of 19.0~26.0 kg/m2 (including boundary values)
- Menstrual cycle regularity, or menstrual regularity before taking oral contraceptives (25-34 days, including boundary values)
- The levels of follicle stimulating hormone(FSH), luteinizing hormone(LH), prolactin (PRL), estradiol (E2), progesterone (P), and testosterone (T) detected within 2-3 days after the last menstrual period before the first administration are within normal ranges or considered abnormal by the researchers to have no clinical significance
- LH levels \&lt;5 IU/L, FSH levels \&lt;4 IU/L at Day -1
Ki nem vehet részt
- Use of any LH preparation, human menopausal gonadotropin (hMG) or human chorionic gonadotropin (hCG) preparation within 3 months prior to screening
- Previously or currently suffering from the following diseases: hypothalamic or pituitary tumors, unexplained ovarian enlargement or cyst, Abnormal uterine bleeding of unknown etiology, malignant tumors of the ovaries, uterus, or breast, active thromboembolic diseases, uncontrollable thyroid or adrenal dysfunction, endocrine disorders such as hyperprolactinemia, polycystic ovary syndrome, ovarian hyperstimulation syndrome (OHSS), and ovarian dysfunction, other malignant tumors or diseases of the hypothalamus, pituitary gland, ovaries, and uterus (excluding uterine fibroids)
- Ectopic pregnancy within 3 months prior to screening
- Prescription medications taken within 14 days or 5 half-lives prior to screening or over-the-counter medications (including proprietary and herbal medications) taken within 7 days or 5 half-lives prior to screening
- Excessive consumption of tea, coffee or caffeinated beverages in the 3 months prior to screening
- Drinking an average of more than 14 standard units of alcohol per week in the three months prior to screening, or inability to abstain from alcohol during the test period, or a positive breathalyser test result on the day of admission
- Smoke at least 5 cigarettes per day in the 3 months prior to screening or not be able to stop using any tobacco-based products during the trial
- Participated in a clinical trial of another drug within 28 days prior to screening and used the test drug, or participated in a clinical trial of a medical device within 1 month prior to screening
- History of blood donation or bleeding \&gt;400 ml within 3 months prior to screening
- Allergy or suspected allergy to any component of the experimental drug, control drug, GnRH, GnRH analogs used in this study
- Presence of clinically significant acute or chronic infection at screening or enrolment。
- Presence of localised disease affecting the hypodermic site, or inability to tolerate hypodermic injections。
- Difficulty in blood collection or inability to tolerate venipuncture, or history of needle or blood sickness
- A history of chronic or serious illness or disease of the liver, kidneys, gastrointestinal tract, endocrine system, cardiovascular, neurological, metabolic, haematological, respiratory, or autoimmune systems or an existing disease of one of the above systems which, in the judgement of the investigator, makes him or her unsuitable for enrolment
- Positive tests for hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, and syphilis spirochete antibody
- History of mental illness, substance abuse, drug dependence, or positive substance abuse screen (morphine, THC, methamphetamine, MDMA, ketamine) on the day of admission
- Abnormalities in vital signs, physical examination, laboratory tests (routine blood, blood biochemistry, urinalysis, coagulation, thyroid function), 12-lead electrocardiogram, liquid-based thin-layer cytometry (TCT), and ultrasound are judged by the investigator to be clinically significant and to warrant participation in the trial
- During pregnancy or breastfeeding, or a positive pregnancy test result. The subject (or his/her partner) is planning to have children (including sperm and egg donation) throughout the trial period and for 3 months after the end of the trial. Unwilling to use one or more non-pharmacological contraceptive methods (e.g. total abstinence, condoms, ligation, etc.) during the trial period
- Subjects who withdrew from the trial for their own reasons and who, in the opinion of the investigator, were otherwise unsuitable to participate in the trial
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 20 és 40 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Kína.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a single-centre, randomised, open-label, single-dose, two-cycle, double-crossover study to compare the pharmacokinetics of SJ04 and Ovidrel® in healthy female subjects. Received a single subcutaneous injection administration of SJ04 Injection or Ovidrel®, both administered at a dose of 250 μg, once per cycle, and cross-administered after a washout period.
A vizsgálat 2 csoportja
- T-R Group (Test-Reference drug)A vizsgált kezelés
SJ04 is injected first and Ovidrel® is injected after 2-week period
Kezelés: T-R (Test-Reference drug)
- R-T Group(Reference-Test drug)A vizsgált kezelés
Ovidrel® is injected first and SJ04 is injected after 2-week period
Kezelés: R-T (Reference-Test drug)
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase I Clinical Trial to Compare the Pharmacokinetics, Safety and Immunogenicity of SJ04 and Ovidrel® in Healthy Female Subjects in China
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- Kérdések a feltételekről
- Forrás: NCT06599528: ki vehet részt
- A regiszteradat frissítve
- 2025. február 10.